

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

MEMORIAL HOSPITAL RESEARCH LABORATORIES

[About Us](#) [Physicians](#) [Clinical Trials](#) [Treatment](#)

[Learn About Cancer & Treatment](#)

The Prasad Adusumilli Lab

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA




Prasad S. Adusumilli, MD

Professor and Deputy Chief, Thoracic Service; Vice Chair for Translational Research, Dept. of Surgery;
Co-Director, MSK Mesothelioma Program; Min H. and Yu-Fan C. Kao Chair in Thoracic Cancers

Research led by Prasad S. Adusumilli focuses on investigation of the tumor immune microenvironment and the development of T-cell-mediated immunotherapy for thoracic malignancies and pleural-based diseases. His team has championed regional immunotherapy delivery strategies, resulting in translation of mesothelin-targeted CAR T-cell immunotherapy for malignant pleural mesothelioma, lung, and breast cancers.



[View Lab Overview \(https://www.mskcc.org/research-areas/labs/prasad-adusumilli/overview\)](https://www.mskcc.org/research-areas/labs/prasad-adusumilli/overview)



Cover Image from J Clin Invest Aug 1 2016. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44



Cover Image from J Clin Invest Aug 1 2016. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44.


Journal of Thoracic Oncology




INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Computing Thoracic Cancer Worldwide

Volume 17, Number 1, January 2022

Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief




Cover Image from J Thoracic Oncology Jan 2022. Gross DJ, Chintala NK, Vaghjiani RG, Grosser R, Tan KS, Li X, Choe J, Li Y, Aly RG, Emoto K, Hua Z, Dux J, Cheema W, Bott MJ, Travis WD, Isbell JM, Li BT, Jones DR, Adusumilli PS. Tumor and Tumor-Associated Macrophage PD-L1 Expression is Associated with Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. J Thorac Oncol. 2022;17(1):89-102.



Cover Image from Cancer Discovery Nov 2021. Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O’Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton H, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, SikderD, Senechal B, Wang X, Travis WD, Gönen M, Rudin CM, Brentjens RJ, Jones RJ, Sadelain M. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748-2763.



Cover Image from J Thoracic Oncology Jan 2018. Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS*. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16-26.



Cover Image from Mol Ther Oncolytics – Vol 4, Mar 17, 2017.





Image from Science Sept 2016. Couzin-Frankel J. (2016, September 2). Second chapter. Science. 353(6303):983-5.5.



Cover Image from Cancer Immunology Research Oct 2023. Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, Bai Y, Banerjee S, Saini J, Xiong Y, Vista WR, Byun AJ, De Biasi A, Zeltsman M, Mayor M, Morello A, Mittal V, Gomez DR, Rimner A, Jones DR, Adusumilli PS. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy. Cancer Immunol Res. 2023 Oct 4;11(10):1314-1331. doi: 10.1158/2326-6066.CIR-22-0840. PMID: 37540803; PMCID: PMC10592183.



Featured News



[How MSK Is Teaching CAR T Cells to Attack Solid Tumors](#)

Read about the latest MSK research to make CAR T therapy effective against solid tumors.



[MSK Awards and Appointments December 2024](#)

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.



[New Design Could Make CAR T Cells a More Effective Immunotherapy for Solid Tumors](#)

Learn how researchers engineered CAR T cells to work better by using a mutation in a gene called c-KIT that drives cancer cell growth.

[View All Featured News](#)

Publications Highlights

[Xiong Y, Taleb M, Misawa K, Hou Z, Banerjee S, Amador-Molina A, Jones DR, Chintala NK, Adusumilli PS. c-Kit signaling potentiates CAR T-cell efficacy in solid tumors by CD28- and IL-2-independent costimulation. *Nat Cancer*. 2023;4\(7\):1001-1015. \[PMID: 37336986\]](#)

[Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, Bai Y, Banerjee S, Saini J, Xiong Y, Vista WR, Byun AJ, De Biasi A, Zeltsman M, Mayor M, Morello A, Mittal V, Gomez DR, Rimner A, Jones DR, Adusumilli PS. Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy. *Cancer Immunol Res*. 2023;11\(10\):1314-1331. \[PMID: 37540803\]](#)

[Adusumilli PS, Zauderer M, Riviere I, ...Jones DR, Sadelain M. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD1 agent pembrolizumab. *Cancer Discov.* 2021 Nov;11\(11\):2748-2763. \[PMID: 34266984\]](#)

[Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest.* 2016;126\(8\):3130-3144. \[PMID: 27454297\]](#)

[Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. *Sci Transl Med.* 2014;6\(261\):261ra151. \[PMID: 25378643\]](#)

[View All Publications](#)

People



Prasad S. Adusumilli, MD

Professor and Deputy Chief, Thoracic Service; Vice Chair for Translational Research, Dept. of Surgery; Co-Director, MSK Mesothelioma Program; Min H. and Yu-Fan C. Kao Chair in Thoracic Cancers

- Physician-scientist Prasad S. Adusumilli studies tumor immunology and the development of T-cell-mediated immunotherapy for thoracic malignancies and pleural-based diseases.

[View physician profile](#)

Physician profile

Members

Lab

Alumni

Lab Affiliations

Achievements

Alfredo Amador Molina

Research Associate


Pratiti Ankola

Bioinformatics Technician

- [The Rodman E. Sheed and Thomas G. Sheed Awarded to Dr. Adusumilli](#)
- [Current NCI Awards Received: R01 CA235667; R01 CA236615; R01 CA292664; UG3/UH3 CA29024](#)
- [Current DoD Award Received: CA200437](#)
- [Published in the Journal Cover Pages listed below: J Clin Invest Aug 2016; Science Sept 2016; J Thorac Oncol Jan 2018; Cancer Discov Nov 2021; J Thorac Oncol Jan 2022; Cancer](#)




Srijita Banerjee
Research Assistant




Lara Cani
Clinical Research Coordinator




Waseem Cheema
Research Project Manager



Navin K Chintala
Senior Research Assistant



Victoria Cranwell
Research Fellow



Bilguun Erkhem-Ochir
Research Associate

[now \(https://www.mskcc.org/research-areas/labs/prasad-adusumilli/postdoctoral-fellow\)](https://www.mskcc.org/research-areas/labs/prasad-adusumilli/postdoctoral-fellow)

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)


Postdoctoral Fellow

[Apply](#)

Vincent Galea
Research Fellow

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical




Nayoung Hong
Research Scholar




Prachi Jalan
Research Technician



Prateek Kulkarni
Research Fellow



Zhaohua Hou
Senior Research Scientist



Caroline Kim- Kiselak
Research Fellow



Valeriya Kuznetsova
Research Fellow

application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.


Prasad S. Adusumilli discloses the following relationships and financial interests:

- Orion Corporation
Professional Services and Activities
- Outpace Bio, Inc.
Professional Services and Activities
- Pluri Biotech Ltd.
Professional Services and Activities


- Affyimmune Therapeutics, Inc.
Professional Services and Activities
- BioArdis LLC
Professional Services and Activities
- Century Therapeutics
Professional Services and Activities
- Crescendo Biologics Limited
Professional Services and Activities
- Novocure
Professional Services and Activities



Mehek Ningoo
Research Scholar



Lawrence Ofriel
Research Technician



John Pintado
Project Manager



Skarlet Rubi
Research Technician



Viviana Rubino
Research Fellow



Jasmeen Saini
Clinical Research Associate


- Professional Services and Activities
- Verismo Therapeutics, Inc.
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)



Meriem Taleb
Research Fellow



Carlos Thomas
Senior Research Assistant



Amina Tidjani
Research Fellow